Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2019 Aug 5. doi: 10.1038/s41571-019-0260-y. [Epub ahead of print]

A reality check of the accelerated approval of immune-checkpoint inhibitors.

Gill J1,2, Prasad V3,4,5,6.

Author information

1
Division of Hematology Oncology, Oregon Health & Science University, Portland, OR, USA.
2
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
3
Division of Hematology Oncology, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
4
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
5
Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
6
Center for Health Care Ethics, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
PMID:
31383994
DOI:
10.1038/s41571-019-0260-y

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center